LENZ Therapeutics【LENZ】銘柄情報

LENZ Therapeutics Inc (LENZ) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

6.77

( 4.15% )

買値

5.16

売値

8.75

出来高

283,738

6.48 日の範囲 6.865

6.285 52 週間の範囲 50.40

時価総額

212.269M

前日終値

6.50

始値

6.48

時刻

6.72

最終取引時間

財務取引量

US$ 1,911,479

VWAP

6.7368

平均取引量 (3 か月)

US$ 910,962

発行済株式数

31,354,394

配当利回り

PER

-1.8

1 株当たり利益 (EPS)

-3.66

歳入

20.99M

純利益

-109M

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was for... LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.lenz-tx.com

本社

Solana Beach, United States

設立

2026

LENZ Therapeutics Inc is listed in the Healthcare sector of the ナスダック市場 with ticker LENZ. The last closing price for LENZ Therapeutics was US$6.50. Over the last year, LENZ Therapeutics shares have traded in a share price range of US$ 6.285 to US$ 50.40.

LENZ Therapeutics currently has 31,354,394 shares in issue. The market capitalisation of LENZ Therapeutics is US$212.27 million. LENZ Therapeutics has a price to earnings ratio (PE ratio) of -1.80.

Form 8-K - Current report

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

SAN DIEGO, June 07, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ, “LENZ” or the “Company”...

LENZ Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Q1 2026 total revenue of $1.9 million, including $1.7 million in VIZZ® product sales Approximately 46,000 paid...

LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.42	-5.84144645341	7.19	7.36	6.285	494202	6.68152503	CS
4	-0.41	-5.71030640669	7.18	8.49	6.285	701133	7.25789043	CS
12	-4.59	-40.4049295775	11.36	11.575	6.285	924128	8.74779474	CS
26	-17.89	-72.5466342255	24.66	24.89	6.285	997830	12.80667785	CS
52	-23.11	-77.3427041499	29.88	50.4	6.285	864281	21.61352197	CS
156	-9.21	-57.634543179	15.98	50.4	6.285	490306	22.08418524	CS
260	-9.21	-57.634543179	15.98	50.4	6.285	490306	22.08418524	CS

LENZ - Frequently Asked Questions (FAQ)

What is the current LENZ Therapeutics Inc share price?

The current share price of LENZ Therapeutics Inc is US$ 6.77

How many LENZ Therapeutics Inc shares are in issue?

LENZ Therapeutics Inc has 31,354,394 shares in issue

What is the market cap of LENZ Therapeutics Inc?

The market capitalisation of LENZ Therapeutics Inc is USD 212.27M

What is the 1 year trading range for LENZ Therapeutics Inc share price?

LENZ Therapeutics Inc has traded in the range of US$ 6.285 to US$ 50.40 during the past year

What is the PE ratio of LENZ Therapeutics Inc?

The price to earnings ratio of LENZ Therapeutics Inc is -1.8

What is the cash to sales ratio of LENZ Therapeutics Inc?

The cash to sales ratio of LENZ Therapeutics Inc is 9.83

What is the registered address of LENZ Therapeutics Inc?

The registered address for LENZ Therapeutics Inc is 201 Lomas Santa Fe Drive, Solana Beach, California, 92075

What is the LENZ Therapeutics Inc website address?

The website address for LENZ Therapeutics Inc is www.lenz-tx.com

Which industry sector does LENZ Therapeutics Inc operate in?

LENZ Therapeutics Inc operates in the Biotechnology & Life Sciences sector

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

LENZ Therapeutics Inc (LENZ)

LENZ Therapeutics Inc (LENZ) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

主要統計と詳細

LENZ Therapeutics Inc について

LENZ 最新ニュース

Form 8-K - Current report

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

LENZ Therapeutics to Participate in Upcoming Investor Conferences

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

LENZ Therapeutics to Participate in Upcoming Investor Conferences

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom

Form S-8 - Securities to be offered to employees in employee benefit plans

LENZ - Frequently Asked Questions (FAQ)

LENZ 取引

LENZ Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

無料で登録してください:

広告を削除する